Axsome Therapeutics clinical trials we track

Check company identity source

Phase 3 22 trials

TrialDrugs studiedStatusPrimary completion
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using SolriamfetolNCT07484217Solriamfetol 150 MGRecruiting2028-12Estimated
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)NCT07717879Solriamfetol Dose A, Solriamfetol Dose BRecruiting2028-06-30Estimated
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)NCT07717892Solriamfetol Dose A, Solriamfetol Dose BRecruiting2028-06-30Estimated
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research DesignNCT07398417AXS-14 (Esreboxetine)Recruiting2028-03Estimated
Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)NCT07766655AXS-05 (dextromethorphan-bupropion), BupropionRecruiting2027-12Estimated
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using SolriamfetolNCT06413433Solriamfetol 150 mg, Solriamfetol 300 mgRecruiting2026-12Estimated
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)NCT06568367Solriamfetol 150 mg, Solriamfetol 300 mgRecruiting2026-12Estimated
Open-Label Safety Study of AXS-14 in Subjects With FibromyalgiaNCT07637162AXS-14 (esreboxetine)Enrolling by invitation2028-05Estimated
A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating DisorderNCT06878976SolriamfetolEnrolling by invitation2027-12Estimated
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHDNCT07773883SolriamfetolEnrolling by invitation2027-12Estimated
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)NCT05972044Solriamfetol 150 mg, Solriamfetol 300 mgCompleted2025-02-07Actual
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolNCT06360419Solriamfetol 300 mgCompleted2024-12-31Actual
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT04947553AXS-05 (dextromethorphan-bupropion)Completed2024-12-03Actual
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)NCT05550207AXS-07 (meloxicam-rizatriptan)Completed2024-11-27Actual
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT05557409AXS-05Completed2024-11-21Actual
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)NCT05113745AXS-12 (reboxetine)Completed2024-11-15Actual
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With NarcolepsyNCT05059223AXS-12 (reboxetine)Completed2024-03-15Actual
Assessing Clinical Outcomes in Alzheimer's Disease AgitationNCT04797715AXS-05Completed2022-11-21Actual
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)NCT04068051AXS-07Completed2020-09-22Actual
Initiating Early Control of Migraine Pain and Associated SymptomsNCT04163185AXS-07 (MoSEIC meloxicam and rizatriptan)Completed2020-03-16Actual
Maximizing Outcomes in Treating Acute MigraineNCT03896009AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, RizatriptanCompleted2019-12-10Actual
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension StudyNCT06736509AXS-05 (dextromethorphan-bupropion)Terminated2025-02-17Actual

Phase 2 / 3 1 trial

TrialDrugs studiedStatusPrimary completion
Addressing Dementia Via Agitation-Centered EvaluationNCT03226522AXS-05, BupropionCompleted2020-04-17Actual

Phase 2 2 trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2027-05-01DayAXS-12 (reboxetine)Axsome Therapeutics, Inc. · AXSMCompany-disclosed PDUFA goal dateAnnounced review targetcataplexy in narcolepsyOpen original source
Read source excerpt

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy FDA sets PDUFA target action date of May 1, 2027

First seen: 25 Sep 2026 · Evidence last checked: 25 Sep 2026

2027-05-01DayAXS-12 (reboxetine)Axsome Therapeutics, Inc. · AXSMCompany-disclosed PDUFA goal dateAnnounced review targetcataplexy in narcolepsyOpen original source
Read source excerpt

Axsome’s NDA for AXS-12 for the treatment of cataplexy in narcolepsy is currently under review by the FDA. The PDUFA target action date is May 1, 2027.

First seen: 02 Nov 2026 · Evidence last checked: 02 Nov 2026

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Long-term Safety. After: Measure: Time from randomization to relapse of binge eating in the RW segment.

Planned enrollment decreased by 64 participants

Before: 300 participants (planned). After: 236 participants (planned).

Primary completion date changed

Before: Dec 2026. After: Dec 2027.

Check registry source